NEW YORK (Reuters Health) – Patients with Huntington’s disease treated with the investigational drug latrepirdine (dimebon) showed signs of improved cognitive function in a 3-month trial, investigators report.…
Gary Small, MD, Director, UCLA Center on Aging, University of California, Los Angeles, discusses a recent study, “Your Brain on Google” in which blood flow patterns were compared…
Joshua Grill, PhD, Director, Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program, UCLA, discusses new therapies for Alzheimer’s Disease. The FDA has currently approved 5 symptomatic therapies…
Joseph Demer, MD, Professor of Opthalmology and Neurology, UCLA David Geffen School of Medicine, discusses double vision, which is not uncommon in the elderly and is traditionally attributed…
Andrew Charles, MD, Professor, Director of Headache Research and Treatment Program, UCLA David Geffen School of Medicine, discusses migraine as a problem of brain excitability and chemistry rather…
NEW YORK (Reuters Health) – In patients with middle cerebral artery occlusion, an alteplase dosage of 0.6 mg/kg IV is comparable to a 0.9 mg/kg dosage for achieving…
NEW YORK (Reuters Health) – Prompt treatment of subclinical and clinical seizures in newborns with hypoxic-ischemic encephalopathy (HIE) can potentially decrease brain injury, according to a prospective trial…
NEW YORK (Reuters Health) – Endovascular treatment of intracranial aneurysms 3 mm or smaller in diameter is difficult and risky — but it’s successful in over 90% of…
NEW YORK (Reuters Health) – Cladribine and fingolimod, the first oral agents for multiple sclerosis (MS), significantly reduce relapse rates, risks of disability progression, and disease activity, according…
NEW YORK (Reuters Health) – In patients with poor-grade subarachnoid hemorrhage, hypertonic saline improves cerebral blood flow and enhances cerebral tissue oxygenation for 4 hours post-infusion, UK researchers…